star ocean magical rasp
"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.
Young Thug Co-Defendant 'Yak Gotti' Stabbed In Jail While Awaiting Verdict
In 2024, curiosity was as intense as a solar eclipse—or even more so. The top Google searches of 2024 reveal a world grappling with major events and everyday mysteries, whether understanding celestial phenomena, untangling political controversies, or keeping up with pop culture. Here are Canadian's most searched "what", "why" and "how" according to Google Trends. In the "What" category, the skies—and the screens—dominated our attention. The most pressing question was, “What time is the solar eclipse?” as people worldwide didn’t want to miss the rare event. Combat sports lovers wanted to know “What time is the Jake Paul vs. Mike Tyson fight?” —an unusual clash of generations. Political intrigue was high with “What is Project 2025?” and “What time is the Presidential debate?” showing the upcoming election’s impact. Meanwhile, concerns about health, language, and technology appeared with questions like “What is Mpox?” , “What does demure mean?” , and “What is CrowdStrike?” The "Why" questions suggest a year of global conflicts, pop culture intrigue, and societal shifts. People sought explanations for pivotal events, from solar safety ( “Why can’t you look at a solar eclipse?” ) to political outcomes ( “Why did Trump win?”). Drake’s influence continued with “Why is Drake trending?” while geopolitical crises drove queries like “Why did Israel attack the Iranian embassy?” and “Why did ISIS attack Moscow?” On a lighter note, Canadian sports fans wanted to know “Why is Nylander not playing?” —a question underscoring the nation’s hockey fervour. The "How" list reflected practical concerns and a thirst for knowledge. Civic-minded searches like “How many electoral votes are there?” and “How to register to vote in the US?” led the charge. Sports remained a priority with “How to watch the Olympics in Canada?” and “How many Canadians on the Florida Panthers?” Health-related questions included “How does being barefoot affect your health?” Meanwhile, the eclipse generated queries like “How long will the eclipse last?” and “How to make solar eclipse glasses?” These top searches reflect a world where people want to be informed, prepared, and entertained—whether by an eclipse, a debate, or a celebrity headline.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. VXRT today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator. "We are pleased to complete the enrollment of the sentinel cohort, an important milestone that reflects the collaboration of our entire team, as well as the trust and commitment of the participants and investigators involved," said Dr. James F. Cummings, Vaxart's Chief Medical Officer. "We look forward to DSMB and FDA review followed by the planned initiation of the Phase 2b trial's second portion. Our continued progress brings us closer to our goal of potentially demonstrating advantages of our mucosal technology against an approved mRNA vaccine." An independent Data and Safety Monitoring Board (DSMB) and the U.S. Food and Drug Administration (FDA) will review 30-day safety data from the sentinel cohort. Upon favorable review by the DSMB and FDA, the study will progress after Biomedical Advanced Research and Development Authority (BARDA) approval to the second part of the trial by enrolling approximately 10,000 participants. The trial will strive to enroll participants in line with U.S. demographics, as well as including at least 25% over the age of 65. The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study to determine the relative efficacy, safety, and immunogenicity of Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA COVID-19 injectable vaccine in adults previously immunized against COVID-19 infection. The full Phase 2b trial will measure efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and the incidence of adverse events. The primary endpoint is relative efficacy of Vaxart's COVID-19 vaccine candidate compared to an approved mRNA comparator for the prevention of symptomatic disease. Primary efficacy analysis will be performed when all participants have either discontinued or completed a study visit 12 months post-vaccination. Funding for this award was received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart's project award through the Rapid Response Partnership Vehicle (RRPV) is valued at up to $456 million. This project has been funded with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); BARDA, under Other Transaction (OT) number 75A50123D00005. As a pioneer of oral vaccines, Vaxart was the first U.S. company to complete a Phase 2 clinical trial of an oral vaccine for COVID-19. About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials and the timing of such results, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," "anticipate," "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart's capital resources may be inadequate; Vaxart's ability to resolve pending legal matters; Vaxart's ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law. Contact Vaxart Media and Investor Relations : Matt Steinberg FINN Partners IR@vaxart.com (646) 871-8481 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The ghosts of Stonewall are watching: How trans activists are channeling history in the fight for their livesMosaic Co. stock falls Friday, underperforms market
Victor Wembanyama plays 1-on-1 chess with fans in New YorkSupreme Court Denies Facebook’s Appeal to Halt Cambridge Analytica Lawsuit From Jilted Investors
Orioles lose 7 prospects in Rule 5 draft, including pitcher Juan NuñezVan Nistelrooy returned to Old Trafford as Erik ten Hag’s assistant in the summer and had a four-game interim spell in charge following his compatriot’s sacking in October. He left the club in the wake of Ruben Amorim’s appointment but was only out of work for two weeks after being appointed Leicester’s new manager on a deal until 2027. The 48-year-old had a glittering playing career with United and was disappointed his return had to end so soon. “The moment I took over the interim job what I said was I’m here to help United and to stay to help United, and I meant it,” he said. “So I was disappointed, yeah, very much so, and it hurt I had to leave. “The only job I would take as an assistant was at United because of the bond that I have with the people in the club and the fans. “But in the end I got my head around it because I also understand the new manager. I’m in football long enough, and I’ve managed myself, that you can think of a situation, me being there, I understand. “I spoke to Ruben about it, fair enough to him, the conversation was grateful, man to man, person to person, manager to manager, and that helped a lot to move on and straightaway get into talks with new possibilities which of course lifted my spirits.” The Dutchman takes on a difficult job at the King Power Stadium as he is tasked with keeping Leicester in the Premier League. He inherits an influential dressing room, which has seen a number of managers come and go over the last few years. Ruud's here for his first press conference as our Manager 😃 pic.twitter.com/A4Juixvorb — Leicester City (@LCFC) December 2, 2024 Van Nistelrooy revealed he has done his due diligence and also let the players know as well. “It’s the only way you can work. It’s mutual respect. I also mentioned to the players yesterday that I looked at the squad and started to make phone calls about players, because in football everyone knows everyone,” he said. “With two or three phone calls you hear stories about 20 players and for me it was important that you hear there are good characters there. That’s important, that there are good people there. “I look at the players how they play. I obviously don’t know them but I got general information and the individuals that they are a good bunch of people. That was important for me to get in.”
Ruud van Nistelrooy ‘disappointed’ and ‘hurt’ after cutting ties with Man Utd